Peptide inhibition of human cytomegalovirus infection by Melnik, Lilia I et al.
RESEARCH Open Access
Peptide inhibition of human cytomegalovirus
infection
Lilia I Melnik, Robert F Garry, Cindy A Morris
*
Abstract
Background: Human cytomegalovirus (HCMV) is the most prevalent congenital viral infection in the United States
and Europe causing significant morbidity and mortality to both mother and child. HCMV is also an opportunistic
pathogen in immunocompromised individuals, including human immunodeficiency virus (HIV)- infected patients
with AIDS, and solid organ and allogeneic stem cell transplantation recipients. Current treatments for HCMV-
associated diseases are insufficient due to the emergence of drug-induced resistance and cytotoxicity, necessitating
novel approaches to limit HCMV infection. The aim of this study was to develop therapeutic peptides targeting
glycoprotein B (gB), a major glycoprotein of HCMV that is highly conserved across the Herpesviridae family, that
specifically inhibit fusion of the viral envelope with the host cell membrane preventing HCMV entry and infection.
Results: Using the Wimley-White Interfacial Hydrophobicity Scale (WWIHS), several regions within gB were
identified that display a high potential to interact with lipid bilayers of cell membranes and hydrophobic surfaces
within proteins. The ability of synthetic peptides analogous to WWIHS-positive sequences of HCMV gB to inhibit
viral infectivity was evaluated. Human foreskin fibroblasts (HFF) were infected with the Towne-GFP strain of HCMV
(0.5 MOI), preincubated with peptides at a range of concentrations (78 nm to 100 μM), and GFP-positive cells were
visualized 48 hours post-infection by fluorescence microscopy and analyzed quantitatively by flow cytometry.
Peptides that inhibited HCMV infection demonstrated different inhibitory concentration curves indicating that each
peptide possesses distinct biophysical properties. Peptide 174-200 showed 80% inhibition of viral infection at a
concentration of 100 μM, and 51% and 62% inhibition at concentrations of 5 μM and 2.5 μM, respectively. Peptide
233-263 inhibited infection by 97% and 92% at concentrations of 100 μM and 50 μM, respectively, and 60% at a
concentration of 2.5 μM. While peptides 264-291 and 297-315, individually failed to inhibit viral infection, when
combined, they showed 67% inhibition of HCMV infection at a concentration of 0.125 μM each.
Conclusions: Peptides designed to target putative fusogenic domains of gB provide a basis for the development
of novel therapeutics that prevent HCMV infection.
Introduction
Human cytomegalovirus (HCMV) is a ubiquitous oppor-
tunistic pathogen that belongs to the Betaherpesviridae.
The virulence of this pathogen is directly linked to the
immune status of its host. Primary HCMV infection is
generally asymptomatic in immunocompetent individuals,
although it causes a mononucleosis-like syndrome in
some. After primary HCMV infection, the virus establishes
lifelong latency and periodically reactivates with notable
pathological consequences. In contrast, HCMV infection
in immunocompromised patien t ss u c ha sA I D Sp a t i e n t s
and solid organ and allogeneic stem cell transplantation
recipients causes serious disease [1]. Primary infection of
women during or right before pregnancy with HCMV is
the most common cause of congenital viral infection lead-
ing to significant morbidity and mortality. Congenital
HCMV infection is also associated with spontaneous abor-
tion, premature delivery, intrauterine growth restriction
(IUGR), and pre-eclampsia. The risk of primary infection
in a seronegative mother is 1 to 4%, which carries a 30 to
40% risk of congenital infection [2,3]. The majority of con-
genitally infected babies are asymptomatic at birth; how-
ever, 10 to 17% subsequently develop hearing defects or
neurodevelopmental sequelae [4]. Although the most
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any medium, provided the original work is properly cited.serious clinical sequelae are seen in cases where a mother
acquires a primary infection during pregnancy, down-
stream side effects are also seen in cases where latent
HCMV is reactivated [5] and where a mother is reinfected
with a different strain of the virus [6].
HCMV has a double-stranded DNA genome of 235 kb
encoding approximately 165 genes [7]. It has a very
broad cellular tropism resulting in potential infection of
nearly every organ system. The ability of HCMV to
enter a wide range of cell types involves a complex
interaction between several viral envelope glycoproteins
and host cell surface receptors, although the entry of
herpesviruses into host cells is still poorly understood.
The HCMV virion envelope contains at least 20 virus-
encoded glycoproteins that are involved in cell attach-
ment and penetration [8]. Of these, glycoprotein B (gB)
is the most abundant glycoprotein [9] and is highly con-
served among the Herpesviridae [10]. Glycoprotein B
plays a critical role in the HCMV entry process. Initially,
gB along with gM/gN, is involved in tethering of virions
to heparan sulfate proteoglycans (HSPG) on the surface
of host cells. The short interaction of HCMV with
HSPG is followed by more stable interactions with one
or more viral cellular receptors, namely epidermal
growth factor receptor (EGFR) [11], platelet-derived
growth factor receptor (PDGFR) [12], and toll-like
receptor TLR-2 [13]. Glycoprotein B also interacts with
integrin avb3, a coreceptor that enhances HCMV entry
[14]. Integrins are known to synergise with EGFR as
well as with other receptors to activate signal transduc-
tion pathways [15-17]. To complete the entry process,
both viral and cellular membranes fuse, allowing the
release of virion-associated tegument and capsid pro-
teins into the cytoplasm. This final step of viral entry
into host cells requires gB and the gH/gL complex
[18-21].
Antibodies to HCMV gB have been shown not only to
block penetration of virions into cells, but also to limit
cell-to-cell infection, implying that gB plays a role in vir-
ion penetration into cells, cell-to-cell transmission, as
well as fusion of infected cells [20,22]. Recently, Isaacson
and coworkers used genetic complementation to con-
firm that gB is required for the fusion of viral and cellu-
lar membranes, virus entry, and cell-to-cell spread of
HCMV [23]. The importance of gB for viral infection
suggests that this viral envelope protein may be a
rational target for novel drug design.
HCMV infection is highly prevalent in the population
due to the ability of the virus to efficiently transmit
between hosts that harbour and periodically shed the
virus. HCMV is transmitted through direct exposure to
infected bodily secretions, including saliva, urine and
breast milk. Following infection, HCMV enters the
bloodstream and spreads to various organs including
k i d n e y ,l i v e r ,s p l e e n ,h e a r t ,b r a i n ,r e t i n a ,e s o p h a g u s ,
i n n e re a r ,l u n g s ,c o l o n ,a n ds a l i v a r yg l a n d s[ 2 4 ] .T h e
ability of HCMV to infect a wide variety of cell types is
n o td u et ot h ep r e s e n c eo fh i g hp l a s m al e v e l so fe x t r a -
cellular virus, but is primarily due to cell-to-cell trans-
mission between mononuclear phagocytes (possibly
macrophages or dendritic cell precursors) and unin-
fected tissues [25].
The lack of a successful HCMV vaccine as well as the
toxicity and drug-induced resistance associated with cur-
rent therapeutics for HCMV indicate that this virus con-
tinues to pose a significant public health problem. Current
treatments for HCMV disease target viral replication and
can fail due to the emergence of drug-resistant virus var-
iants and induction of adverse effects. Hence, a new
approach in drug design against HCMV is required
[26,27]. Since HCMV and other herpesviruses establish a
lifelong latency in humans, antiviral therapy that inhibits
viral entry may serve as an alternative to the already exist-
ing and inadequate therapeutic agents. Here, we report the
design, development and characterization of peptides that
specifically inhibit viral infection and/or entry as a novel
approach to prevent HCMV infection.
Results
HCMV gB is a likely class III viral fusion protein
Structural studies place herpes simplex virus type 1 gB-1
[28] and Epstein-Barr virus gB into class III viral fusion
proteins (VFP) [29], which also includes VSV G [30],
members of the GP64 superfamily (baculovirus and tho-
gotovirus) [31] and tentatively bornavirus G [32].
Because gB is the most highly conserved envelope pro-
tein amongst the mammalian and avian herpesvirues
[25,33], gB of HCMV is likely to be a class III VFP and
shares structural features with gB of other members of
the Herpesviridae. Class III viral fusion proteins share
certain characteristics found in class I or class II viral
fusion proteins. The class III viral fusion proteins con-
tain an extended a-helix that trimerizes in the post-
fusion forms of the proteins [28,30,34], as has been
well-documented for the post-fusion forms of the class I
viral fusion proteins of orthomyxoviruses, retroviruses,
paramyxoviruses, arenaviruses, and coronaviruses [32].
Similarly, the class II viral fusion proteins of flaviviruses
and alphaviruses contain a fusion domain comprised
principally of b-sheets and “fusion loops.” Class III viral
fusion proteins also possess a fusion domain, as well as
several other features of class II viral fusion proteins,
suggesting that these two classes of proteins may share
a common progenitor [31].
The class III domain nomenclature used here can
apply to both class II and class III viral fusion proteins:
domain I (green), domain II (yellow), domain III (blue),
domain IV (stem domain, indigo) (Figure 1). This
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the following: VSV G domain IV in the nomenclature of
Roche et al. [30], HSV-1 gB-1 and baculovirus gp64
domain I in the nomenclature of Heldwein et al.[ 2 8 ]
and Kadlec et al. [31] as the class III fusion domain,
which is structurally similar to class II viral fusion pro-
teins. In addition to minor adjustments in the ends of
domains, the current class III viral fusion protein num-
bering also combines two interacting domains into
domain III (I + II in Roche’s VSV G nomenclature, III +
IV in Heldwein’s HSV-1 gB-1 nomenclature and
Kadlec’s baculovirus nomenclature).
Identification of HCMV gB inhibitory peptides
The Wimley-White Interfacial Hydrophobicity Scale
(WWIHS) is an experimentally determined hydrophobi-
city scale that provides a quantitative description of a
protein partitioning and folding into membrane inter-
faces. WWIHS score-positive sequences may also inter-
act with hydrophobic surfaces within proteins, and are
often sequestered within pre-fusion forms of viral fusion
proteins. In addition to similarities in the overall struc-
ture of the post-fusion forms of class III VFP, there are
additional similarities in the distribution of WWIHS-
positive sequences (Figure 1, red). The similarities
include at least one extended “fusion loop” in the fusion
domain (domain II), and one or more WWIHS score-
positive sequences in domain III. With the exception of
the ACNPV GP64, each of these proteins contains
another WWIHS positive domain II sequence near the
“hinge” region adjacent to the domain. Herpesvirus gB
proteins have an additional WWIHS scale score-positive
sequence in domain I. In the case of class II and III
v i r a lf u s i o np r o t e i n s ,t h ef u s i o nl o o p si nt h ef u s i o n
domain often contain sequences with positive WWIHS
scores.
Previous studies have suggested that synthetic peptides
corresponding to or overlapping with sequences in viral
fusion proteins that have positive WWIHS scores can
sometimes serve as viral entry inhibitors [35-50]. For
example, Enfurvitide (Fuzeon) is a 36-amino acid pep-
tide that overlaps with a WWIHS score-positive
sequence in the transmembrane protein (TM) of HIV-1,
and prevents viral fusion and entry of the virus. To
identify regions of HCMV gB that have a high propen-
sity to interact with the lipid bilayer of cell membranes
and which potentially may serve as HCMV entry inhibi-
tors, we employed Membrane Protein eXplorer version
3.0 (http://blanco.biomol.uci.edu/mpex), a computer
program based on the WWIHS. Nine sequences with
significant positive WWIHS scores were identified
(Figure 2). As expected, several of these WWIHS
sequences corresponded to the predicted fusion domain
of HCMV gB, including the predicted fusion loops. One
of the WWIHS score-positive sequences spanned amino
acids 146 to 200 (peptide 146-200) that had a ΔGs c o r e
of 4.33 kcal/mol. This sequence was split into two smal-
ler peptides: 146-173 and 174-200. A second large
Figure 1 Wimley-White interfacial hydrophobicity scale score-positive sequences in class II and III viral fusion proteins. Sequences of a
representative class II viral fusion protein (Dengue virus E) and of class III viral fusion proteins with high potential to interface with lipid
membranes (red) were identified using Membrane Protein Explorer software (MpeX version 3.0). As discussed in the text, a class III domain
nomenclature is used here that can apply to both class II and III viral fusions proteins. The alternative domain number schemes used by Roche
et al. and Heldwein et al. are noted in parentheses. The Dengue virus (DENV E) stem domain sequence that was not included in the protein
used to determine the crystal structure has been added. The DENV stem has a positive WWIHS scale score, and corresponds to a previously
determined inhibitor of DENV and West Nile virus [35].
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ΔG score of 3.39, and was split, consequently, into smal-
ler peptides: 233-263 and 264-291. An additional pep-
tide, 297-315 corresponding to another fusion domain
sequence, was also synthesized, along with an additional
4 peptides corresponding to other WWIHS-positive
domains of HCMV gB. To prevent dimer formation,
cysteines were replaced with alanines.
Nine synthetic peptides corresponding to sequences
with significant WWIHS scores were synthesized and
examined for their ability to inhibit HCMV infection of
HFF cells. Peptides that were most effective are pre-
sented here (Table 1). All synthetic peptides were tested
at the following concentrations: 100 μM, 50 μM, 25 μM,
10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM,
0.156 μM, and 0.078 μM. HFF were seeded at a density
of 3.5×10
5 cells in each well of a 24-well plate 24 hours
prior to infection. HFF were washed with 1× DPBS and
mock- or virus-infected for 90 minutes at RT with the
Towne-GFP strain of HCMV (0.5 MOI) preincubated
with different concentrations of inhibitory peptides at
37°C for 90 minutes. After infection, virus was removed
and Dulbecco’s modified Eagle medium (DMEM) sup-
plemented with 10% fetal bovine serum (FBS), penicillin
G (100 U/mL), streptomycin (100 mg/mL), and Gluta-
MAX (2 mM) was added to each well and cells were
incubated at 37°C for 48 hours. GFP-positive cells were
visualized 48 hours post-infection by fluorescence
microscopy and then quantified using flow cytometry.
Peptide 174-200, for instance, demonstrated 80% inhi-
bition of viral infection at a concentration of 100 μM,
and 51% and 62% inhibition at concentrations of 5 μM
and 2.5 μM, respectively (Figure 3). Peptide 233-263
inhibited viral infection by 97% and 92% at concentra-
tions 100 μM and 50 μM, respectively, and by 60% at a
concentration of 2.5 μM (Figure 4). The scrambled pep-
tide (control), of peptide 233-263, was unable to inhibit
HCMV infection significantly (data not shown). While
peptide 264-291, alone, showed inhibition of 70.5%, at a
concentration of 5 μM (Figure 5), peptide 297-315
tested alone showed 40% inhibition at a concentration
of 50 μM (Figure 6). None of the remaining peptides
showed significant inhibition of HCMV infection at any
of the concentrations tested (data not shown). In addi-
tion to testing individual peptides in viral infectivity
assays, peptides were similarly tested in combination.
Interestingly, when peptides 174-200 and 233-263 were
tested together, no significant inhibitory effect was
shown (Figure 7). On the contrary, peptides 264-291
and 297-315 tested together displayed 67% inhibition at
a concentration of 0.125 μM each (Figure 8). Represen-
tative fluorescent and bright light images of HFF cells
infected with the Towne-GFP strain of HCMV (0.5
MOI) preincubated with or without peptide 233-263 at
a concentration of 100 μM were taken 48 hours post-
infection (Figure 9).
Discussion
The WWIHS is a computational approach, based upon
an experimentally determined algorithm to estimate the
propensity of an amino acid sequence to interact with
lipid membrane interfaces [49]. Using this method, we
identified several regions of HCMV gB with high inter-
facial hydrophobicity. Peptides that are analogous to
several of these regions inhibited HCMV infectivity at
low μM concentrations (Figure 3, 4, 5, 6, 7 and 8).
When tested in combination certain combinations of
peptides (peptides 264-291 and 297-315) displayed
increased inhibition of infectivity at concentrations of
125 nM (Figure 8). These results suggest that the
HCMV inhibitory peptides identified here may serve as
Figure 2 Determination of regions within gB that display a
high propensity to interact with the lipid surface of cell
membranes by using Wimley-White Interfacial Hydrophobicity
Scale (WWIHS). WWIHS identifies segments of proteins that prefer a
transbilayer helix conformation to an unfolded interfacial location.
We used the Interface Scale of the Membrane Protein explorer
(MpeX version 3.0) computer program to identify these particular
segments of HCMV gB. The Interface scale measures a residue’s free
energy of transfer within an unfolded polypeptide chain from water
to a phosphocholine bilayer. We identified nine segments of HCMV
gB that display high propensity to interact with the lipid surface of
cell membrane, and designed peptides, ranging from 19 to 31
amino acids in length, that are analogous to the identified regions
of gB.
Table 1 Amino acid sequences of HCMV gB peptides
Peptide Amino acid sequence Position
174-200 WEIHHINKFAQAYSSYSRVIGGTVFVA 174-200
233-263 WHSRGSTWLYRETANLNAMLTITTARSKYPY 233-263
264-291 HFFATSTGDVVYISPFYNGTNRNASYFG 264-291
297-315 FFIFPNYTIVSDFGRPNAA 297-315
HCMV gB peptides were synthesized based on the amino acid sequence
determined from GenBank accession no. DAA00160 (Human Herpesvirus 5
strain AD169).
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Page 4 of 11Figure 3 Inhibition of HCMV infection by peptide 174-200. HFF were seeded at a density of 3.5×10
5 cells in each well of a 24-well plate 24
hours prior to infection. The inhibitory effect of peptide 174-200 was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-
GFP strain of HCMV (0.5 MOI) preincubated with different concentrations of inhibitory peptide 174-200 at 37°C for 90 minutes. GFP-positive cells
were visualized 48 hours post-infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the
number of GFP-positive cells compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using
one-way ANOVA and Tukey’s post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56]
and FreeHand (Macromedia). Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I,
and blue-domain III with extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that
correspond to HCMV gB domains are shown in black.
Figure 4 Inhibition of HCMV infection by peptide 233-263. HFF were seeded at a density of 3.5×10
5 cells in each well of a 24-well plate 24
hours prior to infection. The inhibitory effect of peptide 233-263 was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-
GFP strain of HCMV (0.5 MOI) preincubated with different concentrations of inhibitory peptide 233-263 at 37°C for 90 minutes. GFP-positive cells
were visualized 48 hours post-infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the
number of GFP-positive cells compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using
one-way ANOVA and Tukey’s post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56]
and FreeHand (Macromedia). Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I,
and blue-domain III with extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that
correspond to HCMV gB domains are shown in black.
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Page 5 of 11Figure 5 Inhibition of HCMV infection by peptide 264-291. HFF were seeded at a density of 3.5×10
5 cells in each well of a 24-well plate 24
hours prior to infection. The inhibitory effect of peptide 264-291 was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-
GFP strain of HCMV (0.5 MOI) preincubated with different concentrations of inhibitory peptide 264-291 at 37°C for 90 minutes. GFP-positive cells
were visualized 48 hours post-infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the
number of GFP-positive cells compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using
one-way ANOVA and Tukey’s post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56]
and FreeHand (Macromedia). Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I,
and blue-domain III with extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that
correspond to HCMV gB domains are shown in black.
Figure 6 Inhibition of HCMV infection by peptide 297-315. HFF were seeded at a density of 3.5×10
5 cells in each well of a 24-well plate 24
hours prior to infection. The inhibitory effect of peptide 297-315 was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-
GFP strain of HCMV (0.5 MOI) preincubated with different concentrations of inhibitory peptide 297-315 at 37°C for 90 minutes. GFP-positive cells
were visualized 48 hours post-infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the
number of GFP-positive cells compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using
one-way ANOVA and Tukey’s post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56]
and FreeHand (Macromedia). Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I,
and blue-domain III with extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that
correspond to HCMV gB domains are shown in black.
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Page 6 of 11Figure 7 Additive effect of HCMV gB peptides 174-200 and 233-263 on HCMV infection. HFF were seeded at a density of 3.5×10
5 cells in
each well of a 24-well plate 24 hours prior to infection. The ability of peptides 174-200 and 233-263 to work together and their effect on
inhibition of virus infection was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-GFP strain of HCMV (0.5 MOI)
preincubated with different concentrations of inhibitory peptides at 37°C for 90 minutes. GFP-positive cells were visualized 48 hours post-
infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the number of GFP-positive cells
compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using one-way ANOVA and Tukey’s
post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56] and FreeHand (Macromedia).
Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I, and blue-domain III with
extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that correspond to HCMV gB domains
are shown in black.
Figure 8 Additive effect of HCMV gB peptides 264-291 and 297-315 on HCMV infection. HFF were seeded at a density of 3.5×10
5 cells in
each well of a 24-well plate 24 hours prior to infection. The ability of peptides 264-291 and 297-315 to work together and their effect on
inhibition of virus infection was evaluated by infecting human foreskin fibroblasts (HFF) with the Towne-GFP strain of HCMV (0.5 MOI)
preincubated with different concentrations of inhibitory peptides at 37°C for 90 minutes. GFP-positive cells were visualized 48 hours post-
infection by fluorescence microscopy and then quantified using flow cytometry. Significant reductions in the number of GFP-positive cells
compared to HCMV infected cells are denoted by a * (p < 0.05), ** (p < 0.01), and *** (p < 0.001, determined using one-way ANOVA and Tukey’s
post test). All structural figures of HSV-1 gB in the post-fusion configuration were generated using MacPyMOL [56] and FreeHand (Macromedia).
Different domains of gB are shown in the ribbon structures: yellow-fusion domain II, purple-stem, green-domain I, and blue-domain III with
extended a-helices, which are involved in trimerization. Peptides targeting different domains of HSV-1 gB that correspond to HCMV gB domains
are shown in black.
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Page 7 of 11the basis for potential antiviral therapies. The success of
the inhibition of fusion greatly depends, not only on
biophysical properties of synthesized peptides and their
concentrations, but also on the size and shape of the
binding pocket of HCMV gB. It is possible that the
potency of the peptides, either alone or in combination,
can be increased by modifying the sequence of the
peptides or by conjugating the peptide(s) to other
molecules.
Akkarawongsa and coworkers prepared a library of
overlapping peptides homologous to the ectodomain of
Herpes Simplex Virus Type 1 (HSV-1) gB-1 and
screened for the ability of these peptides to block infec-
tion [50]. Seven out of 138 15-mer peptides inhibited
infection by more than 50% at a concentration of 100
μM. Three peptides (gB131, gB122 and gB94) with 50%
effective concentrations below 20 μMw e r es t u d i e d
further. Peptide gB131 (residues 681 to 695 in HSV-1
gB-1) was identified as a specific entry inhibitor (EC50,
~12 μM). The gB122 peptide (residues 636 to 650 in
gB-1) blocked viral entry (EC50,~ 1 8μM), protected
cells from infection (EC50, ~72 μM), and inactivated vir-
ions in solution (EC50, ~138 μM). Of the seven inhibi-
tory peptides identified in the Akkarawongsa et al.
study, three of them, corresponding to residues 346 to
360 (gB64), 436 to 450 (gB82), and 636 to 650 (gB122),
were in regions of HSV-1 gB-1 with positive WWIHS
scores. The success of their study affirms our strategy of
targeting the WWIHS score-positive sequences as inhi-
bitors of HCMV. Two overlapping peptides spanning
the residues 496 to 510 (gB94) and 501 to 515 (gB95)
were not in WWIHS score-positive sequence, but the
analogous sequence in HCMV is WWIHS score-posi-
tive. Additionally, comparisons across viral families
could potentiate identification of entry inhibitors. For
instance, HSV-1 inhibitory peptide gB131 corresponding
to domain IV, also known as a stem, is analogous to the
Hrobowski dengue inhibitory peptide for the class II
viral fusion proteins [35] (Figure 1).
The most potential inhibitors of HCMV infection
were all in domain II. HSV-1 inhibitory peptide gB64
(residues 346 to 360) identified by Akkarawongsa et al.
corresponds to this region, with HCMV inhibitory pep-
tide 297-315 being the analogous peptide (Figure 10). It
is possible that some of the inhibitory peptides identified
for HSV-1 could be optimized to work for HCMV and
vice versa. The fusion domain of HCMV gB may be the
initial site of interaction directly with the lipids of the
cell bilayer [31]. The HCMV inhibitory peptides could
competitively block these interactions, or trigger down-
stream fusion events, and conformational changes in gB,
prematurely. Inhibitory peptides corresponding to other
domains likely do not block lipid interactions. Inhibitory
Figure 9 Bright light and fluorescent images representing the
ability of peptide 233-263 to inhibit infection by the Towne-
GFP strain of HCMV. (A-B) Representative fluorescent and bright
light microscopic images of HFF infected with the Towne-GFP strain
of HCMV (0.5 MOI). (C-D). Representative fluorescent and bright light
images of HFF infected with the Towne-GFP strain of HCMV (0.5
MOI) preincubated with peptide 233-263 at a concentration of
100 μM.
Figure 10 Comparison of HSV-1 gB-1 inhibitory peptide and
HCMV gB inhibitory peptides. Of the seven HSV-1 gB-1 inhibitory
peptides (346-360, 436-450, 496-510, 501-515, 576-590, 636-650, 681-
6950) [50’, three peptides (346-360, 436-450, 636-650) are both
inhibitory and WWIHS score-positive. Two overlapping inhibitory
peptides (496-510 and 501-515) are not in WWIHS score-positive
sequences, but the analogous sequence in HCMV is WWIHS score-
positive. The most potent inhibitors of HCMV infection are all in
domain II (174-200, 233-263, 264-291, 297-315). HSV-1 inhibitory
peptide gB64 (346-360) corresponds to this region of HCMV gB.
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therefore those that are analogous to domain III could
block receptor interactions.
As the result of this study we found that the effects of
several of the HCMV inhibitory peptides did not follow
a linear dose-dependent inhibition curve. This trend was
also reported previously describing peptide inhibitors of
Dengue and West Nile viruses [35]. Possibly, when the
concentration of one or more peptides is too high, the
peptides may self-associate, preventing them from inter-
fering with virus infectivity.
In addition to screening synthetic peptides for their
ability to inhibit HCMV infection alone, we tested some
peptides in combination. It is possible that peptides
264-291 and 297-315 block HCMV entry at distinct
steps in the fusion process. Any two peptides that work
additively to block the fusion of the virion with the host
cell membrane must have unique amino acid sequences,
biophysical properties and be present at certain concen-
trations that will allow them to interact with each other,
with gB and, possibly, with other glycoproteins that are
instrumental in the fusion event. Peptides 174-200 and
233-263 tested together showed only 42% inhibition at
the concentration of 50 μM each (Figure 7), and did not
work in an additive fashion. This result may be due to
peptide-peptide interactions that do not allow interfer-
ence with gB trimer formation and with necessary con-
formational changes of the virion required for successful
fusion to occur.
Several drugs, including ganciclovir, its oral prodrug
valganciclovir, foscarnet, cidofovir, and fomivirsen have
been approved for the treatment of HCMV-associated
disease. All of these drugs, with the exception of fomi-
virsen, have a common target, the viral DNA polymer-
ase [26]. The above listed anti-HCMV drugs provoke
not only drug-specific side effects, which include leuko-
penia, thrombocytopenia, anemia, bone marrow hypo-
plasia, diarrhea, and renal toxicity, but also the
emergence of clinically relevant drug-resistant HCMV
[27]. New drugs that are more efficacious and are not
toxic in treatment of HCMV infection are urgently
needed.
The inhibitory peptides identified here can serve as
the basis for the development of a novel therapeutic
against HCMV. These antiviral agents could be used as
an antiviral treatment to reduce the viral load in preg-
nant women and neonates. It is not clear how HCMV
infects the fetus during pregnancy, but some studies
demonstrate that placental infection with HCMV occurs
before the transmission of the virus to the fetus and
suggest that the placenta plays a role in vertical trans-
mission of HCMV from mother to fetus. Also, placental
viral infection has been implicated in spontaneous abor-
tion during early pregnancy that occurs in fifteen
percent of women with primary HCMV infection. Pla-
cental pathology as a result of HCMV infection during
pregnancy may also cause premature delivery, intrauter-
ine growth restriction (IUGR), or pre-eclampsia [51-54].
Enfurvitide, a 36-amino acid peptide also known as
Fuzeon works by inhibiting the structural rearrangement
of HIV-1 gp41 to block the fusion of HIV-1 virions with
their target cell membrane. Brennan-Benson et al.
showed that Fuzeon prevents vertical transmission of
HIV-1 in pregnancy, but does not cross the placenta
[55]. We have shown that some peptides are effective at
preventing HCMV infection. Those lead peptides will be
studied further and modified to increase their efficacy,
solubility and delivery.
Currently available drugs to treat HCMV infection are
not approved to treat pregnant women due to their
potential high toxicity. HCMV infected neonates are
treated with these toxic compounds only in cases of
high morbidity. The antiviral peptide-based agents that
may be developed as a result of this study would not
require activation by virally encoded proteins, further
phosphorylation by cellular enzymes or incorporation
into the growing viral DNA by viral DNA polymerase as
the current therapeutics do. Such peptide therapeutics
would be predicted not to provoke drug-induced resis-
t a n c et h a ti sas i g n i f i c a n tp roblem with existing FDA-
approved therapeutics to treat HCMV infection, since
they employ a different mechanism of action. Our cell
viability assays demonstrate that the effective peptides
have no statistically significant toxicity at the highest
concentrations tested in our studies (data not shown).
Consequently, we do not expect adverse effects or toxi-
city due to treatments developed from these synthetic
peptides.
Methods
Design and Synthesis of peptides
WWIHS is an experimentally determined algorithm that
can be used to estimate the propensity of amino acid
sequences to interact with lipid membrane interfaces [49].
Sequences of HCMV gB with positive WWIHS score were
identified using Membrane Protein explorer (MpeX ver-
sion 3.0) (http://blanco.biomol.uci.edu/mpex), a computer
program based on WWIHS. HCMV gB synthetic peptides
were synthesized by solid phase conventional N-a-9-fluor-
enylmethyloxycarbonyl chemistry by Genemed Synthesis
Inc. (San Francisco, CA). Peptides were purified by
reverse-phase high performance liquid chromatography
and confirmed by amino acid analysis and electrospray
mass spectrometry. Peptide stock solutions were prepared
in 10% dimethyl sulfoxide (DMSO, spectroscopy grade):
90% (v/v) H2O. Peptide concentrations were determined
by absorbance of aromatic side chains at 280 nm (Smart-
Spec ™ 3000, BioRad, Hercules, CA).
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The Towne strain of HCMV containing the green fluores-
cent protein (GFP) expression cassette was obtained from
Dr. Daniel Streblow at the Oregon Health Science Univer-
sity and was propagated in human foreskin fibroblasts
(HFF). Viral supernatants were collected 5 days after 100%
CPE was observed, centrifuged to clear cell debris, and fil-
tered through a 0.45 μm filter. HFF were grown in Dulbec-
co’s modified Eagle medium (DMEM) supplemented with
10% fetal bovine serum (FBS), penicillin G (100 U/mL),
streptomycin (100 mg/mL), and GlutaMAX (2 mM).
Viral infectivity assays
HFF were seeded at a density of 3.5×10
5 cells in each
well of a 24-well plate 24 hours prior to infection. HFF
were washed with 1× DPBS and mock- or virus-infected
for 90 minutes at RT with the Towne-GFP strain of
HCMV (0.5 MOI) preincubated with different concen-
trations of inhibitory peptides at 37°C for 90 minutes.
After infection, virus was removed and Dulbecco’s mod-
ified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), penicillin G (100 U/mL),
streptomycin (100 mg/mL), and GlutaMAX (2 mM) was
added to each well and cells were incubated at 37°C for
48 hours. GFP-positive cells were visualized 48 hours
post-infection by fluorescence microscopy and then
quantified using flow cytometry.
Flow Cytometry
HFF cells were trypsinized, centrifuged, and resuspended
in 1% FBS DPBS. GFP-positive cells were quantified
using flow cytometry (Cytomics FC 500 Beckman Coul-
ter, Fullerton, CA).
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